首页> 外国专利> Omalizumab or its pharmaceutically acceptable salts (xolair)

Omalizumab or its pharmaceutically acceptable salts (xolair)

机译:奥马珠单抗或其药学上可接受的盐(xolair)

摘要

Compsn. comprises a pure human-like immunoglobulin (Ig) which (a) reacts specifically with p55 Tac protein and/or (b) inhibits binding of human interleukin-2 (IL-2) to its receptor. Also new are (1) human-like Ig having 2 pairs of light/heavy chains and able to react specifically with an epitope of a human IL-2 receptor with affinity at least 10 power 8 per mole, the chains including complementarily determg. regions (CDR's) and human-like framework regions (FR's), the CDR's being from different Ig molecules than FR's; (2) humanised Ig (hIg) which can bind to IL-2 receptors and contain at least one CDR from anti-Tac antibody in a human-like FR contg. at least one amino acid from the anti-Tac antibody; (3) nucleic acid encoding for human-like FR and at least one murine CDR, and (4) cells transfected with nucleic acid.
机译:Compsn。包含纯人样免疫球蛋白(Ig),其(a)与p55 Tac蛋白特异性反应和/或(b)抑制人白介素2(IL-2)与其受体的结合。 (1)具有2对轻/重链的人样Ig也是新的,并且能够与人IL-2受体的表位特异性地以每摩尔至少10次幂8的亲和力反应,所述链包括互补确定的。区域(CDR)和人样框架区域(FR),CDR来自与FR不同的Ig分子。 (2)人源化Ig(hIg),其可与IL-2受体结合并在人样FR contg中含有至少一个来自抗Tac抗体的CDR。来自抗Tac抗体的至少一个氨基酸; (3)编码人样FR和至少一个鼠CDR的核酸,和(4)被核酸转染的细胞。

著录项

  • 公开/公告号LU91208I2

    专利类型

  • 公开/公告日2006-02-28

    原文格式PDF

  • 申请/专利权人 PROTEIN DESIGN LABS INC.;

    申请/专利号LU20050091208C

  • 发明设计人

    申请日2005-12-02

  • 分类号A61K39/395;C12N5/10;C12N7/01;C12N15/00;C12N15/13;C12P21/00;C12P21/08;

  • 国家 LU

  • 入库时间 2022-08-21 21:38:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号